|  | | 
 | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | |
|
| | | 
| |  | |
News Hub Callendar
| < January 2009 | | Su | M | T | W | T | F | S | | | 1 | 2 | 3 |
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
|
| |
|
| | New Data Suggest Differences In Clinical Performance Between The CYPHER® Sirolimus-Eluting ... |
|
date: Mar 14th 2006 15:08
page: 1 | 2
Stent And The Taxus Stent In Long Complex Lesions.
Data from a multi-center, prospective randomized controlled clinical trial suggests that the CYPHER® Sirolimus-eluting Coronary Stent outperformed the Taxus Stent in procedures involving long coronary lesions, which are considered some of the most complex blockages to treat with angioplasty. The results from the LONG DES-II Study were presented here today at the American College of Cardiology Conference Annual Scientific Session.
The LONG DES-II Study (percutaneous treatment of long native coronary lesions with Drug-Eluting Stents II) was designed to compare the angiographic in-segment binary restenosis rate of CYPHER® Stent vs. the Taxus Stent at six months. The study was conducted across five medical centers in Korea and included 500 patients (250 in the CYPHER® Stent arm and 250 in the Taxus Stent arm). Lesion length needed to be > 25 mm. It is estimated that long lesions such as these comprise approximately 20 percent of cases treated by interventional cardiologists today.
In this study, the CYPHER® Stent showed better outcomes than the Taxus Stent in these complex, long lesions. Patients with very long lesions are among the most difficult to treat and tend to be at higher risk of restenosis, said Seung-Jung Park, M.D., Ph.D., FACC, principal investigator of this study and Chief of Interventional Cardiology, ASAN Medical Center, Seoul, Korea. These findings provide important new information for clinicians to consider when choosing the best treatment for these types of complex patients.
Myeong-Ki Hong, M.D., PhD., associate professor of Medicine, Division of Cardiology, Department of Internal Medicine, University of Ulsan, College of Medicine, Seoul, Korea, presented the findings today on Dr. Park s behalf. The ASAN Medical Center is the teaching affiliate hospital of Ulsan University, also in Korea.
In this study, the patients received a mean total stent length of about 41 mm. Patients receiving the CYPHER® Stent had significantly less in-stent late loss than patients treated with the Taxus Stent (0.05±0.22 loss index for the CYPHER® Stent vs. 0.25±0.35 loss index for the Taxus Stent p<0.001) and 71 percent less in-segment restenosis than patients treated with the Taxus Stent (three percent for the CYPHER® Stent vs. 10.3 percent for the Taxus Stent p=0.007).
Additionally, patients treated with the CYPHER® Stent had significantly larger minimal in-stent diameter (vessel opening) at follow-up than patients treated with the Taxus Stent (2.39±0.46 mm for the CYPHER® Stent vs. 2.04±0.65 for the Taxus Stent p<0.001), which is important for blood flow, and a lower average in-stent diameter stenosis (blockage) than those treated with the Taxus Stent (13.0±17.8 percent for the CYPHER® Stent vs. 23.6±20.7 percent for the Taxus Stent p<0.001) at late follow-up.
Secondary endpoints included in-segment and in-stent restenosis at six months as well as Major Adverse Cardiac Events (MACE), an important safety and efficacy outcome measure which comprises all-cause death, myocardial infarction (heart attack) and target lesion revascularization (TLR or retreatment). At the nine-month clinical follow-up, MACE rates were three percent for the CYPHER® Stent versus 7.8 percent for the Taxus Stent (p=0.027).
The LONG DES-II trial provides additional clinical evidence that continues to differentiate the CYPHER® Stent from the Taxus Stent, said Dennis Donohoe, M.D., vice president, Worldwide Clinical and Regulatory Affairs, Cordis Corporation.
page: 1 | 2
article 'New Data Suggest Differences In Clinical Performance Between The CYPHER® Sirolimus-Eluting ...' source is Johnson & Johnson, visit source site:
Articles by information source
News and articles by category
News and articles by day |
|
